Stock listing

NASDAQ:VRCA Verrica Pharmaceuticals Inc. Stock

Home listing (NASDAQ) of Verrica Pharmaceuticals Inc.

Follow Verrica Pharmaceuticals Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VRCA

$3.60 USD -0.18 (-4.9%)

Close on Oct 16, 2026

Since Jul 6, 2026 -41.4% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$3.48 – $3.95 USDOct 16, 2026
Volume
116,473 sharesOct 16, 2026
Market value
$61.76M USDAt the close on Oct 16, 2026 · price × 17.18M shares outstanding
Verrica Pharmaceuticals Inc. logo
Ticker
NASDAQ:VRCA
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Verrica Pharmaceuticals (NASDAQ:VRCA) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 2026 Earnings Call

    Tue, May 12, 2026 · 4:30 PM ET

    Watch Transcript

  • Verrica Pharmaceuticals (NASDAQ:VRCA) Q4 2025 Earnings Call

    Wed, Mar 11, 2026 · 8:15 AM ET

    Watch Transcript

Latest news

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Sep 30, 2026

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

Sep 10, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Aug 27, 2026

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Aug 6, 2026

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

Aug 6, 2026

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Jul 30, 2026

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Jul 21, 2026

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Jun 22, 2026

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

All Verrica Pharmaceuticals Inc. news

Decks

Verrica Pharmaceuticals Inc. on 6ix

News releases
26 in the last 12 months · 140 in all · newest Sep 30, 2026 · oldest 2019
Calls
11 calls with a replay · 11 with a transcript · latest Aug 6, 2026
Decks
22 decks · latest September 2026

Where Verrica Pharmaceuticals Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VRCA · Home listing · This pageNASDAQUnited StatesUSD
Lang & Schwarz:A41A98Lang & SchwarzGermanyEUR
Tradegate:1NE0TradegateGermanyEUR
BOATS:VRCABOATSUnited StatesUSD
gettex:1NE0gettexGermanyEUR
LS Exchange:A41A98LS ExchangeGermanyEUR
Frankfurt:1NE0FrankfurtGermanyEUR
Stuttgart:1NE0StuttgartGermanyEUR
Munich:1NE0MunichGermanyEUR

Log in to ask 6ix AI your own questions about Verrica Pharmaceuticals Inc.